
Shares of Monte Rosa Therapeutics GLUE.O jump 35.6% to $6.52
*Stock set for its biggest one-day pct. gain in over 10 months, if gains hold
Company says it has entered into an agreement to collaborate with Swiss drugmaker Novartis NOVN.S to develop drugs for immune-mediated diseases
The deal includes an upfront payment of $120 million to Monte Rosa, with the company eligible for a total of up to $5.7 billion in milestones and option payments across programs
Wedbush analyst Robert Driscoll says the deal represents additional validation of Monte Rosa's molecular glue degrader discovery platform from an existing large‑pharma partner
U.S.-listed shares of Novartis down 1% at $122.81
Including session move, GLUE down 6.6%, NVS up 26% YTD